Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.
相关临床试验
5
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
2
40.0%
终止
3
60.0%
暂无批准数据
- Aethlon Medical and North Immunology have signed a definitive all-stock merger agreement to advance NOR-101, a half-life extended IL-13 x IL-18 bispecific antibody for atopic dermatitis. - An oversubscribed $180 million private placement backed by Bain Capital Life Sciences, Janus Henderson and others is expected to fund operations into the second half of 2028. - A Phase 1a study of NOR-101 is expected to begin in the first quarter of 2027, with interim pharmacokinetic and safety data anticipated by mid-2027. - North Immunology investors will own approximately 95.25% of the combined company, which will trade on Nasdaq under the ticker NRTX after an expected first-quarter 2027 close.
- Patients with Long COVID exhibited approximately two-fold higher levels of mannose-positive extracellular vesicles compared to individuals who fully recovered from COVID-19, according to new peer-reviewed research published in the International Journal of Molecular Sciences. - The study, conducted with UCSF investigators, demonstrated that GNA affinity resin — the active binding component of the Hemopurifier — successfully captured disease-associated extracellular vesicles and significantly reduced seven circulating microRNAs linked to immune regulation and inflammatory signaling. - Computational pathway analysis suggested modulation of JAK-STAT, VEGF, PI3K, and Estrogen signaling pathways implicated in Long COVID, establishing a mechanistic link between disease-associated EVs and the Hemopurifier's lectin-based capture technology. - Aethlon Medical's primary focus remains its Australian oncology clinical trial, but these findings provide translational evidence supporting future studies evaluating the Hemopurifier as a potential treatment for Long COVID.
- Aethlon Medical published preclinical data showing its Hemopurifier device successfully removes extracellular vesicles from Long COVID patient plasma samples and reduces inflammatory microRNAs. - The study found significantly elevated mannose-positive extracellular vesicles in Long COVID patients compared to recovered controls, providing a potential therapeutic target. - The device's GNA affinity resin depleted seven microRNAs associated with inflammatory pathways, including JAK-STAT, which is currently being targeted in Long COVID clinical trials. - Long COVID affects an estimated 44-48 million Americans with a $2 billion economic burden, yet no effective treatment currently exists despite over $1 billion in research funding.
- Aethlon Medical's Hemopurifier showed encouraging changes in extracellular vesicles, microRNAs, and lymphocytes in cancer patients not responding to anti-PD-1 therapy. - Envoy Medical received FDA approval to expand its pivotal trial for the fully implanted Acclaim cochlear implant, shortening commercialization timeline by 3-6 months. - Soligenix's Data Monitoring Committee confirmed no safety concerns for HyBryte in treating cutaneous T-cell lymphoma, with topline results expected in H2 2026. - MBX Biosciences achieved statistical significance in its Phase 2 trial of canvuparatide for chronic hypoparathyroidism, with 63% of patients meeting the primary endpoint.
- Aethlon Medical successfully treated the first three patients in its Hemopurifier cancer trial at Australian hospitals, with all participants completing 4-hour treatments without device deficiencies or immediate complications. - The company received regulatory approval from India's Central Drugs Standard Control Organization to initiate a similar oncology study at Medanta Medicity Hospital. - Preclinical data demonstrated 98.5% removal of platelet-derived extracellular vesicles, supporting potential applications in multiple diseases including cancer, Long COVID, and autoimmune conditions. - The trial protocol was expanded to include patients receiving combination therapies with Pembrolizumab or Nivolumab, reflecting current immunotherapy treatment practices.
- Aethlon Medical successfully treated a second patient with its investigational Hemopurifier device in an Australian clinical trial targeting solid tumors resistant to anti-PD-1 therapies. - Both patients in the first cohort completed 4-hour treatments without device deficiencies or immediate complications, with safety data to be reviewed by an independent Data Safety Monitoring Board. - The approximately 18-patient trial aims to evaluate whether removing tumor-derived extracellular vesicles can improve response rates to pembrolizumab or nivolumab, which currently show lasting responses in only 30-40% of patients. - The Hemopurifier holds FDA Breakthrough Device designation and is designed to bind and remove extracellular vesicles implicated in cancer metastasis and immunotherapy resistance.
- Aethlon Medical will present pre-clinical data at the Keystone Symposium showing their Hemopurifier device can bind extracellular vesicles from Long COVID patients. - The study, conducted with UC San Francisco, found that extracellular vesicles from Long COVID participants contain mannose targets that bind to the device's proprietary affinity resin. - Long COVID affects 44-48 million Americans with a $2 billion economic burden, yet no effective treatments exist despite over $1 billion in research funding. - The Hemopurifier is an FDA Breakthrough Device that uses lectin-based technology to remove harmful extracellular vesicles implicated in Long COVID pathogenesis.
- Aethlon Medical reports that its Hemopurifier device demonstrated 99% removal of H5N1 influenza virus in in vitro testing after 6 hours. - The Hemopurifier, an investigational extracorporeal device, targets enveloped viruses via the mannose on their surface using GNA lectin. - The device has Breakthrough Device designation from the FDA for life-threatening viruses without effective treatments. - Aethlon is prepared to engage with hospitals, California, and the FDA should H5N1 cases increase and current treatments prove insufficient.
• Aethlon Medical has enrolled the first two patients in its Hemopurifier® trial in Australia, targeting solid tumors unresponsive to anti-PD-1 antibodies. • The trial is a safety, feasibility, and dose-finding study, with two Australian sites now actively enrolling patients and an additional site in India approved. • Strategic cost-cutting measures are being implemented to optimize resource allocation, focusing on high-impact areas of the oncology trial. • The Hemopurifier aims to remove extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies.
- Aethlon Medical has enrolled and treated the first patient in its Australian clinical trial of the Hemopurifier device for solid tumors. - The trial focuses on patients with stable or progressive disease despite anti-PD-1 monotherapy like pembrolizumab or nivolumab. - The Hemopurifier aims to improve response rates by removing tumor-derived extracellular vesicles (EVs) from the bloodstream. - The study's primary endpoint is safety, with secondary measures evaluating changes in EV concentrations and anti-tumor T cell activity.
